Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 6/2007

Open Access 01-12-2007 | Research

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

Authors: Emily C Lutterloh, Steven M Opal, Debra D Pittman, James C Keith Jr, Xiang-Yang Tan, Brian M Clancy, Helen Palmer, Kim Milarski, Ying Sun, John E Palardy, Nicholas A Parejo, Noubar Kessimian

Published in: Critical Care | Issue 6/2007

Login to get access

Abstract

Introduction

The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily, contributes to acute and chronic disease processes, including sepsis.

Methods

We studied the possible therapeutic role of RAGE inhibition in the cecal ligation and puncture (CLP) model of polymicrobial sepsis and a model of systemic listeriosis using mice genetically deficient in RAGE expression or mice injected with a rat anti-murine RAGE monoclonal antibody.

Results

The 7-day survival rates after CLP were 80% for RAGE-/- mice (n = 15) (P < 0.01 versus wild-type), 69% for RAGE+/- mice (n = 23), and 37% for wild-type mice (n = 27). Survival benefits were evident in BALB/c mice given anti-RAGE antibody (n = 15 per group) over serum-treated control animals (P < 0.05). Moreover, delayed treatment with anti-RAGE antibody up to 24 hours after CLP resulted in a significant survival benefit compared with control mice. There was no significant increase in tissue colony counts from enteric Gram-negative or Gram-positive bacteria in animals treated with anti-RAGE antibody. RAGE-/-, RAGE+/-, and anti-RAGE antibody-treated animals were resistant to lethality from Listeria monocytogenes by almost two orders of magnitude compared with wild-type mice.

Conclusion

Further studies are warranted to determine the clinical utility of anti-RAGE antibody as a novel treatment for sepsis.
Appendix
Available only for authorised users
Literature
1.
Rice TW, Bernard GR: Therapeutic intervention and targets for sepsis. Annu Rev Med 2005, 56: 225-248. 10.1146/annurev.med.56.082103.104356CrossRefPubMed
2.
Cross AS, Opal SM: A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med 2003, 138: 502-505.CrossRefPubMed
3.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCE, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267: 14998-15004.PubMed
4.
Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, et al.: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992, 267: 14987-14997.PubMed
5.
Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000, 1498: 99-111. 10.1016/S0167-4889(00)00087-2CrossRefPubMed
6.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al.: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97: 889-901. 10.1016/S0092-8674(00)80801-6CrossRefPubMed
7.
Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM: Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000, 105: 1117-1124.PubMedCentralCrossRefPubMed
8.
Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, et al.: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002, 3: 123-135. 10.1038/sj.gene.6363861CrossRefPubMed
9.
Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, et al.: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198: 1507-1515. 10.1084/jem.20030800PubMedCentralCrossRefPubMed
10.
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105: 816-822. 10.1161/hc0702.104183CrossRefPubMed
11.
Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11: 1656-1666.PubMed
12.
Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995, 270: 25752-25761. 10.1074/jbc.270.43.25752CrossRefPubMed
13.
Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, et al.: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000, 6: 643-651. 10.1038/76216CrossRefPubMed
14.
Seong S-Y, Matzinger P: Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4: 469-478. 10.1038/nri1372CrossRefPubMed
15.
16.
Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279: 7370-7377. 10.1074/jbc.M306793200CrossRefPubMed
17.
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101: 296-301. 10.1073/pnas.2434651100PubMedCentralCrossRefPubMed
18.
Treutiger CJ, Mullins GE, Johansson A-SM, Rouhiainen A, Rauvala HME, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, et al.: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254: 375-385. 10.1046/j.1365-2796.2003.01204.xCrossRefPubMed
19.
Liliensiek B, Weigand MA, Beirhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Gröne HJ, Kurschus FC, Schmidt AM, et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113: 1641-1650. 10.1172/JCI200418704PubMedCentralCrossRefPubMed
20.
Echtenacher B, Falk W, Männel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990, 145: 3762-3766.PubMed
21.
Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108: 949-955. 10.1172/JCI200114002PubMedCentralCrossRefPubMed
22.
Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, et al.: RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002, 59: 1117-1128. 10.1007/s00018-002-8491-xCrossRefPubMed
23.
24.
Wing EJ, Gregory SH: Listeria monocytogenes : clinical and experimental update. J Infect Dis 2002,185(suppl 1):S18-24. 10.1086/338465CrossRefPubMed
Metadata
Title
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection
Authors
Emily C Lutterloh
Steven M Opal
Debra D Pittman
James C Keith Jr
Xiang-Yang Tan
Brian M Clancy
Helen Palmer
Kim Milarski
Ying Sun
John E Palardy
Nicholas A Parejo
Noubar Kessimian
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6184

Other articles of this Issue 6/2007

Critical Care 6/2007 Go to the issue

Research

Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review

Research

Changes in sedation management in German intensive care units between 2002 and 2006: a national follow-up survey

Research

Cerebral haemodynamics and carbon dioxide reactivity during sepsis syndrome

Letter

Does serum procalcitonin have a diagnostic value in febrile adult patients presenting to the emergency department?

Commentary

Novel biomarkers in critical care: utility or futility?

Book report

Richard S Irwin, James M Rippe, Alan Lisbon, Stephen O Heard: Procedures, Techniques, and Minimally Invasive Monitoring in Intensive Care Medicine, 4th Ed., Lippincott Williams & Wilkins. 375 pages.